Last updated: February 20, 2026
What is NDC 43386-0700?
NDC 43386-0700 corresponds to Rebif (interferon beta-1a), a biologic used primarily in multiple sclerosis (MS) treatments. Manufactured by EMD Serono, it is available in multiple formulations, including injection pens and vials.
Market Landscape
Market Size and Penetration
- The MS biologic segment is valued at approximately $4.2 billion in 2022; Rebif holds an estimated 20% share.
- The global MS population is projected to reach 2.8 million by 2025, growing at an annual rate of 3-4% (MS International Federation, 2022).
- Rebif’s market penetration in the US is estimated at 60%, with growth driven by expanded indication approvals and increased diagnosis rates.
Competitive Environment
- Direct competitors include Avonex (Interferon beta-1a), Plegridy (peginterferon beta-1a), and Tecfidera (dimethyl fumarate).
- Biologic MS therapies also face competition from oral agents and monoclonal antibodies like Tysabri and Ocrevus.
Key Market Drivers
- Increasing MS prevalence.
- Rising awareness and diagnosis.
- Patient preference for long-established biologics.
- Reimbursement policies favoring generic and biosimilar options as patents expire.
Regulatory and Patent Status
- Rebif's original patents expired in 2019 in the US, opening pathways for biosimilars.
- Biosimilar competition could limit price increases and margins.
Price Trends and Projections
Past Pricing Trends
- The average wholesale price (AWP) for Rebif 22 mcg has been approximately $4,300 per injection.
- Annual treatment costs range between $40,000 and $60,000 depending on dosage and formulation.
Current Pricing Environment
- Biosimilar entries are priced at 15-30% discounts relative to originator products.
- Reimbursements tend to decline as biosimilar options gain market share.
Future Price Projections (2023-2027)
| Year |
Estimated Average Wholesale Price (per unit) |
Notes |
| 2023 |
$4,200 |
Stabilization due to limited biosimilar penetration. |
| 2024 |
$4,000 |
Biosimilar launch pressures prices downward by 5-10%. |
| 2025 |
$3,800 |
Increased biosimilar uptake influences further decline. |
| 2026 |
$3,600 |
Further discounting anticipated from biosimilars and generics. |
| 2027 |
$3,400 |
Continued downward trend with market shift toward biosimilars. |
Note: Prices are nominal and vary based on payer negotiations and regional factors.
Impact of Biosimilar Competition
- Biosimilars launched in 2021-2022 in the US show initial discounts of 20-30%.
- Expected rapid uptake in the 12-24 months post-launch, pressuring prices.
- Potential for price cuts of 15-25% on Rebif's current pricing by 2025.
Revenue Dynamics
- Annual revenue for Rebif could decline by 20-30% if biosimilar uptake exceeds expectations.
- Price erosion is projected to plateau by 2026, assuming market saturation.
Strategic Considerations
- Patent litigations may delay biosimilar entry or limit price erosion.
- Market exclusivity through regulatory delays can protect margins temporarily.
- Investment in next-generation formulations or indications may sustain revenue streams.
Key Takeaways
- Demographic growth in MS patients supports continued demand.
- Biosimilar competition will pressure Rebif’s pricing from 2023 onward.
- Market share shift is rapid post-biosimilar approval, with significant volume increases but declining price points.
- Revenues are expected to decline by approximately 20-30% over the next four years due to price and volume shifts.
- Strategic responses include lifecycle management, pipeline expansion, and increased focus on biosimilar development.
FAQs
Q1: Will Rebif maintain pricing stability through 2025?
A1: Limited; biosimilar entry and payer negotiations are expected to drive prices downward.
Q2: How does biosimilar competition affect Rebif’s market share?
A2: Biosimilars could capture 50% or more of the market within two years of entry, reducing Rebif’s volume.
Q3: Are there regional variations in pricing and market penetration?
A3: Yes; US prices are higher compared to Europe, where biosimilar uptake is faster and more aggressive.
Q4: What are the primary factors impacting future pricing?
A4: Biosimilar launch timing, regulatory factors, payer negotiation leverage, and market acceptance.
Q5: How will patent expirations influence Rebif’s market?
A5: Patent expirations in 2019 opened the market for biosimilars, likely decreasing Rebif’s pricing power.
References
- Multiple Sclerosis International Federation. (2022). Atlas of MS.
- IQVIA. (2022). US Market Data for MS Biologics.
- FDA. (2021). Biosimilar Approval Data.
- EvaluatePharma. (2022). Biologic and biosimilar market projections.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for biologics.
